FagronLab | 2021 Ensuring homogeneity in powder mixtures for pharmaceuticals and dietary supplements: Evaluation of a 3-axis mixing equipment Marianni B, Polonini HC, Oliveira MAL Pharmaceutics, 3(4), 563-572 The study evaluated the efficacy of a new 3-axis mixer device. Three formulations were compounded, a total of 540 individual tests were performed, and two alternative methods were compared. The 3-axis device provided homogeneous mixtures and finished capsules with adequate content uniformity, and proved superior to classical mixing methods. Read more
ImunoTF | 2021 Characterization and safety profile of Imuno TF®, a nutritional supplement for immune system regulation containing transfer factors Polonini HC, de Souza Schmidt Gonçalves AE, Dijkers E, Ferreira AO Biomolecules, 11(5), 665-676 This study demonstrates the proteomic analysis, nutritional composition, and safety profile of Imuno TF®, a complex set of 163 different peptides, 10 vitamins, and 11 minerals. The chemical composition showed low fat and sugar content and no saturated fatty acids. No mutagenic effect was observed. Read more SEE PRODUCT
Cleoderm | 2021 Cleoderm™ Clarifying Cream: A novel, topical vehicle using plant-based excipients and actives targeting acne and oily skin Polonini HC, Zander C, Radke J Journal of Cosmetics, Dermatological Sciences and Applications, 11(4), 422-426 In this paper, Cleoderm is presented as a ready-to-use vehicle for the compounding of acne treatments and products for oily skin. Evidence shows multiple positive roles of Cleoderm including a decrease in sebum production, lipid peroxidation, and reactive oxygen species, inhibition of Cutibacterium acnes proliferation, and control of inflammation. Read more SEE PRODUCT
Pentravan | 2021 Assessment of the effect of structural modification of Ibuprofen on the penetration of Ibuprofen from Pentravan® (Semisolid) formulation using human skin and a transdermal diffusion test model Ossowicz-Rupniewska P, Nowak A, Klebeko J, Janus E, Duchnik W, Adamiak-Giera U, Kucharski L, Prowans P, Petriczko J, Czapla N, Bargiel P, Markowska M, Klimowicz A Materials, 14(22), 6808-6826 The effect of Pentravan® on skin permeability was examined for unmodified ibuprofen (IBU) and ion pairs of ibuprofen with new L-valine alkyl esters. The resulting Pentravan-based creams with ibuprofen in the form of an ionic pair represent a potential alternative to other forms of the drug-containing analgesics administered transdermally. Read more SEE PRODUCT
Pentravan | 2021 Compatibility of Gestrinone, Nimesulide, and Piroxicam in Pentravan® for transdermal and transmucosal application Polonini HC, Ferreira AO, Dijkers E International Journal of Pharmaceutical Compounding, 25(5), 422-426 In this work, the compatibility of Pentravan and three active pharmaceutical ingredients was determined: gestrinone, a steroidal substance for vaginal use, and nimesulide and piroxicam, two nonsteroidal anti-inflammatory drugs used for topical and vaginal application. This article shows an excellent beyond-use date of 180 days when stored at room temperature. Read more SEE PRODUCT
Pentravan | 2021 Compatibility of different formulations in Pentravan® and Pentravan® Plus for transdermal drug delivery Polonini HC, Taylor S, Zander C Scientia Pharmaceutica, 89(4), 51 In this study, the stability in Pentravan®/Plus of danazol, metformin HCl, and resveratrol, as well as metformin HCl, resveratrol, and Vitamin D3 in combinations at bracketed high/low concentrations, were evaluated over a period of 6 months. All formulations presented a beyond-use date of at least 6 months. Read more SEE PRODUCT
Phytobase Cream | 2021 Stability of Fagron’s phytobase cream compounded with various hormones Wynn T, Taylor S, Zander C International Journal of Pharmaceutical Compounding, 25(2), 156-162 The objective of this study was to evaluate the stability of estrone (0.1-1%), estradiol (0.05-2%), estriol (0.05-2%), progesterone ( 0.1-20%), testosterone (0.1-20%), combination (estradiol 0.05%, estriol 0.05%, progesterone 0.5%), and combination (estradiol 2%, estriol 1%, progesterone 20%). The beyond-use date was 180 days in all samples except estrone (150 days). Read more SEE PRODUCT
ImmunoFormulation | 2020 ImmunoFormulation for COVID-19 Diaz M Encyclopedia, online The study describes the cases of four COVID-19 patients that used a combination of Imuno TF®, Miodesin®, and SiliciuMax® for improvement of their symptoms. The four showed improvement in general symptoms after treatment, representing a good starting point to further investigate this possible add-on therapy in controlled clinical studies. Read more
ImmunoFormulation | 2020 Evolution of COVID-19 patients treated with ImmunoFormulation, a combination of nutraceuticals to reduce symptomatology and improve prognosis: a multi-centered, retrospective cohort study Diaz Hernandez M, Urrea J, Bascoy L medRxiv, online The study followed the progression of COVID-19 in patients treated with ImmunoFormulation (IF) versus untreated patients. Throughout the observational period, 90% of patients recovered in the IF cohort (47.4% in the Control cohort). Symptom duration was shorter in the IF cohort, especially for fever, dry cough, dyspnoea, diarrhoea, and weakness. Read more
ImmunoFormulation | 2020 Postulated adjuvant therapeutic strategies for COVID-19 Ferreira AO, Polonini HC, Dijkers E Journal of Personalized Medicine, 10(3), 80-113 This review gives the scientific background on the hypothesis that Imuno TF®, Miodesin®, and SiliciuMax® can act in synergy in the prevention and improvement of COVID-19-associated symptoms. Read more